Monday, 11 May 2020

Distraction Osteogenesis Devices Market 2023 – Market Size, Share, Trends Analysis And Growth Forecast

Market Scenario:
Global Distraction Osteogenesis Devices Market Insights asserts, the market is expected to grow significantly over the forecast period. Distraction osteogenesis is the biological process of the new bone formation between bone segments which are gradually separated by incremental traction.  
Numerous factors such as advancements in distractor devices such as miniaturized internal and external devices, easily placeable and easy handling are expected to drive the growth of the market. For instance, In May 2018, DePuy Synthes, a part of the Johnson & Johnson Medical Devices Companies, announced an exclusive agreement in the US between DePuy Synthes Sales, Inc. and Prosidyan to promote the Fibergraft family of products, a line of synthetic bone graft materials which are ultra-porous, designed for ease of use, and have been engineered for ideal resorption in clinical use during spine fusion surgery. By adding Fibergraft to its offerings, DePuy Synthes will further enhance the company’s portfolio of biomaterials and distractors.
Moreover, various risks such as failure to follow the distraction protocol and damages to nerves hamper the market growth during the assessment period.
Key players
Johnson & Johnson Services, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, KLS Martin Group, Osteomed, Acumed LLC, Jeil Medical Corporation, Ningbo Cibei Medical Treatment Appliance Co., Ltd. Ortho Max Manufacturing Company Pvt. Ltd., Ortho Care and Titamed are some of the key players in the global distraction osteogenesis devices market.
Segmentation
The Global Distraction Osteogenesis Devices Market has been segmented into device type, age, application, and end-user.
The market, based on device type, has been segmented into mandibular distraction devices, palatal distraction devices, alveolar distraction devices, craniofacial distraction devices, Lefort distraction devices, small bone distraction devices, and others. The market, based on craniofacial distraction devices, has been further segmented into external and internal distractors. The market, based on external distractors is further classified into unidirectional distractors, bidirectional distractors, and multiplanar distractors whereas the market, based on, internal distractors can be classified into tooth-borne distractors, bone-borne distractors, and hybrid distractors. The market, by age, has been segmented into pediatrics and adults. The market, by application, has been segmented into dentistry, podiatry, orthopedics, and others. The market, by end-user, has been segmented into hospitals, orthopedic clinics, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Distraction Osteogenesis Devices Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European distraction osteogenesis devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Distraction Osteogenesis Devices Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The distraction osteogenesis devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Geographically, North America is expected to dominate the global distraction osteogenesis devices market owing to increasing number of procedures for treating facial abnormalities in the US. Also, most of the key players have their research and development teams working in this field in the US which in turn increases the awareness among the people about the technique in this region.
The European market is expected to be the second-largest due to increase in initiatives taken by public and private organizations in this field.
Posted by at No comments:

Global Cardiopulmonary Disease Diagnostics and Treatment Market 2019 Analysis By Manufacturers, Latest Trends, Competitive Landscape And Strategies

Market Scenario:
The cardiopulmonary disease is a general term used to describe a variety of different diseases and conditions related to heart and lungs. Cardio Vascular Disease is a complex disease with a wide variety of risk factors including those that are modifiable, such as physical inactivity, non-modifiable factors such as age, genes, congenital dispositions, and gender. Respiratory disease is a medical term that includes extreme conditions affecting the organs and tissues which make gas exchange possible in higher organisms. Depending upon the type of cardiopulmonary disease present the treatment options vary and may include changes in diet or lifestyle, use of medications issued on prescription or surgery. The most common cardiopulmonary diseases are hypertension, stroke, and coronary heart disease. Untreated, cardiopulmonary diseases can be deadly. Cardiopulmonary diseases are the major cause of death globally.
The substantial growth in the frequency of health conditions related to the lungs and heart is the key factor to boosts the growth of this market. Also, the increase in aged population and the rising frequency in cardiovascular and respiratory diseases is also anticipated to drive the global market over the forecast period. Exposure to nicotine, tobacco products, and others increases the risk of obtaining cardiopulmonary diseases.
Increase in the rise of advanced technological equipment for diagnosing the disease will drive market rate exponentially. However, the huge cost of treatment and the regulatory nature of government on pharmaceutical companies will hamper the Cardiopulmonary Disease Diagnostics and Treatment market growth.
Key Players
  • Cardinal Health
  • Cosmed Medical
  • GE Healthcare
  • Halma plc
  • Hill-Rom Holdings, Inc.
  • Koninklijke Philips N.V.
  • MGC Diagnostics Corporation
  • NIHON KOHDEN CORPORATION
  • Schiller AG
  • Masimo Corporation
  • Vyaire Medical Inc
Segmentation
The global cardiopulmonary disease diagnostics and treatment market has been segmented on the basis of disease type, type, and end-user.
On the basis of disease type, the market has been classified as cardiovascular and respiratory diseases. The cardiovascular diseases are segmented into coronary artery disease, angina pectoris, myocardial infarction, dysrhythmia, hypertension, and others. The respiratory diseases are segmented into influenza, asthma, bronchitis, emphysema, cystic fibrosis, and others.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis market is segmented into an electrocardiogram (ECG), Holter monitoring, echocardiogram, stress test, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), stress blood pressure monitors, pulse oximeters and spirometry. The treatment market is segmented into medications. The medications segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBS), anticoagulants, antiplatelet agents and others.
The European cardiopulmonary disease diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The cardiopulmonary disease diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiopulmonary disease diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Posted by at No comments:

Verrucous Carcinoma Market 2019 - Shares, Revenue, Analysis And Forecasts Till 2023

Market Insights
Verrucous Carcinoma typically debuts as an anomalous growth or as alteration in the constancy of an earlier potentially malignant ailment of the oral cavity. Verrucous Carcinoma is a rare, locally aggressive, clinically exophytic, low-grade, slow-growing, well-differentiated squamous cell carcinoma with nominal metastatic potential. It is unusual subtype of malignant ailment which affects oral cavity. Verrucous Carcinoma can affect all mucosal sites of the oral cavity. However, the frequency of malignant transformation of a leukoplakia to an OVC is considerably higher if they are in the gums in comparison to the tongue.
Verrucous Carcinoma is mainly caused by the snuffing of tobacco or chewing of tobacco. It is also referred to as snuff dipper's cancer. Verrucous Carcinoma mostly prevails at oral zones. The condition common in males within the age group 50 to 80 years. The increasing incidences of oral cancer primarily influences the market. Lifestyle factors such as smoking marijuana or tobacco and alcohol consumption mostly drives the Verrucous Carcinoma market. Additionally, growing consumption of alcohol, increasing adoption of sedentary lifestyle, increasing rates of sexually transmitted viruses by human papillomavirus, and family history of cancer prevalence contribute largely towards the development of the market. In 2015, the World Health Organization reported that 1.1 billion people smoked tobacco globally. This is likely to accelerate the market growth over the forecast period.
However, the high cost of surgical procedures, side effects associated with treatments, and expensive chemotherapy treatments are anticipated to limit the market growth to a certain extent.
Market Segmentation
The worldwide Verrucous Carcinoma market has been segmented based on treatment, end-user, and diagnosis.
Based on treatment, the Verrucous Carcinoma market has been segmented into radiation therapy, surgery, targeted drug therapy, and chemotherapy. Surgery has been sub-segmented into Mohs micrographic surgery and surgical excision. Chemotherapy has been sub-segmented into 5-fluorouracil, bleomycin, methotrexate, cisplatin, and others. Based on end-user, the Verrucous Carcinoma market has been segmented into ambulatory surgical centers, hospitals and clinics, research centers, diagnostic centers, and others. Based on diagnosis, the Verrucous Carcinoma market has been segmented into endoscopy, imaging tests, and biopsy. Imaging tests have been sub-segmented into magnetic resonance imaging, positron emission tomography scans, and computerized tomography scans.
Regional Analysis
The Americas represent the largest Verrucous Carcinoma market share in the global market. The market growth is owing to the increasing healthcare expenditure and surging prevalence of Human Papillomavirus (HPV). As recorded by the Genital HPV Infection, Fact Sheet 2017, 79 million American adults were infested with HPV. Europe (Belgium, UK, Netherlands, and France) represents the second largest Verrucous Carcinoma market over the forecast period. Rising prevalence of head and neck cancer drives the Verrucous Carcinoma market in this region. The Cancer Research UK revealed that in 2015, there were12061 new instances of neck and head cancer. These statistics substantially drive the Verrucous Carcinoma market in Europe.
In 2017, Asia-Pacific was estimated to be the fastest growing region for the worldwide Verrucous Carcinoma market. The market has been expected to develop owing to the rising addiction to smoking. According to the World Health Organization, in 2015, 33.7% and 47.6% of people smoked tobacco in Japan and China, respectively. The Middle East and Africa holds the least market share due to lack of availability of trained healthcare professionals and low per capita income in the region. Nevertheless, the growing palliative and oncology care services both at the community and the hospital level are expected to influence the market positively.
Key Players
The global Verrucous Carcinoma market is dominated by key players such as Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Bristol-Myers Squibb Company (US), Eli Lilly and Company. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Europe), Pfizer Inc. (US), Novartis AG (Europe), and others.
Posted by at No comments:

Thursday, 7 May 2020

Global Heart Tumor Market 2020 Industry Analysis, Share, Growth, Trends and Forecast 2023

Heart Tumor Market Scenario
According to the surgery and autopsy reports, primary cardiac tumors are rare with an incidence rate of about 0.3%-0.7%. Malignant primary cardiac sarcomas are usually located in the right atrium of the heart and are most commonly angiosarcomas. The malignant primary cardiac tumors are often diagnosed in young patientswho have a poor prognosis and survival rate of only 10% According to the WHO, the prevalence of melanoma skin cancers has been increasing from the past few decades. Furthermore, 132,000 melanoma skin cancers cases are reported each year across the globe.
The Global Heart Tumor Market Size is expected to grow at a CAGR of approximately 7.1% during the forecast period.
Cardiac tumors is a rare disease that are difficult to diagnose. They are divided on the basis of type into primary and secondary tumors. The prevalance of the secondary tumors is higher than the primary tumors. Majority of the primary cardiac tumors are benign in origin. The high incidences of metastatic tumors  is attributed to various types of  cancers such as lung, breast, renal cancer, lymphomas and melanomas. Clinical manifestations of these tumors generally based on  the size and location of the tumors and spread to the adjacent tissues rather than the type of the tumor itself.  Echocardiography is the major tool used for diagnosis of the tumors. Other imaging modalities include cardiac MRI, cardiac CT, and 3D echocardiography, which may offer some additional information with histological examination.
A small percentage of cardiac tumor cases are hereditary, the tumors can also be associated with another health condition, such as LAMB Syndrome, Carney Syndrome or NAME Syndrome. However, most often, the tumor develops without being associated with any health condition or presence of a family history. They result from cell overgrowth but mostly cardiac tumors results from metastatic condition, where cells from other cancerous organ such as lung and breast, soft-tissues and metastasizes to the heart.
Heart Tumor Market Key Players
Some of key the players in the Global cardiac tumor market are Tomtec Imaging Systems GmBh, Koninklijke Philips N.V., Siemens Healthineers, Circle Cardiovascular Imaging Inc., Toshiba Corporation, Shimadzu Corporation, CardioComm Solutions Inc., Integer Holdings Corporation, Pie Medical Imaging, HeartSciences, 3mensio Medical Imaging, and eMedica, S.L.

Heart Tumor Market Segmentation
The heart tumor is segmented on the basis of type, diagnosis, treatment.
On the basis of the type, the market is segmented into primary tumors and secondary tumors. The primary tumors are divided into benign and malignant. The benign tumors is further categorized into myxoma, papillary heart tumors, fibromas, rhabdomyomas, angioma, and lipomas. The malignant tumors are divided into rhabdomyosarcoma, mesenchymomas, neurosarcoma, fusiform cell tumors, malignant heart hemangioma, and lymphosarcoma. The secondary tumor is categorized into metastatic and contiguity. The metastatic secondary tumors are divided into hematogenic and lymphatic and the contiguity is sub categorized into mediastinal tumors, lung tumors and oesophageal, or cardia tumor.
On the basis of the diagnosis, the market is classified into echocardiogram, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), radionuclide imaging, Position Emission Tomography (PET) Scan, myocardial biopsy, cardiac catherization, and electrophysiology test.
On the basis of the treatment, the market is classified into surgery, chemotherapy, radiation therapy. Furthermore, the surgery is further categorized into open heart surgery, minimal invasive surgery, and heart transplant surgery 
International Heart Tumor Market Regional Analysis
The global heart tumor market consists of four major regions: the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas dominate the market owing to the rising awareness among people and increasing healthcare expenditure. The type of tumors also aids in selection of treatment procedure. For instance, in patient with heart cancers, the results of cardiac imaging could be used to see if the the tumor is spread to the adjacent tissues, which can be further used to remove the portion by performing excision surgery or pursuing treatment with medications.
Posted by at No comments:

Encephalomalacia Market Growth Analysis, Industry Trends, and Forecast by 2023

Market Scenario
Softening or loss of brain tissue is termed as encephalomalacia and is a severe type of brain damage. Encephalomalacia disorder can also be classified into the three categories depending on their colors and the stages of damage i.e. red softening yellow softening, and white softening. The major causes of encephalomalacia are inflammation or hemorrhages that are a consequence of being afflicted by cerebral infarction, cerebral ischemia, infection, craniocerebral trauma, or another injury. Moreover, stroke is the most commonly known cause of encephalomalacia and stroke can be caused by either a head injury or a brain hemorrhage or both of them cause internal bleeding in brain. Furthermore, strokes occur due to reduced or interrupted blood supply to the brain, which is caused by blocked arteries or a burst blood vessel. Moreover, people with diabetes, blood sugar levels that become too high (hyperglycemia) or too low (hypoglycemia) which increases chances of strokes.
People who have been rescued from drowning or those who have been resuscitated after a heart attack may not awaken due to lack of oxygen to the brain. Furthermore infections such as encephalitis and meningitis cause swelling or inflammation of the brain, spinal cord or the tissues that surround the brain in severe cases of these infections can result in brain disorder.
Increasing prevalence of neurological disorders, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods to boost to the Encephalomalacia market. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases will fuel the market growth during the forecast period
Furthermore, globalization in healthcare has increased the market growth. Established market players in the developed countries leads the globalization by pushing new products and services into the developing countries and emerging economies. 
According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high-income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden, which is expected to increase further over the coming years.
However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.
The global encephalomalacia market is expected to grow at a CAGR of ~6.1% during the forecast period 2017-2023.
Key Players
Some of key the players in the market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others.
Segmentations
The global encephalomalacia market is segmented on the basis of types, diagnosis, treatment, and end user.
On the basis of the type, it is segmented into leukoencephalomalacia (encephalomalacia affecting the white matter), and polioencephalomalacia (encephalomalacia affecting the gray matter).  
On the basis of the diagnosis, it is segmented into blood test, brain scans, and others. A brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG).
On the basis of the treatment, it is segmented into medical treatment, surgery, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research laboratories, and others.
Regional Analysis
The Americas dominate the global encephalomalacia market owing to well-developed technology, increasing prevalence of brain disorder, high health care spending, and increasing government support for research & development in the healthcare sector. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
Europe holds the second position in the global encephalomalacia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.     
The Asia Pacific is the fastest growing encephalomalacia market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across th`e globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.   
On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Posted by at No comments:

Spongiform Encephalopathy Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2023

Market Scenario
Transmissible spongiform encephalopathy (TSEs) or prion diseases are a group of invariably fatal conditions that affect central nervous system (CNS) and more specifically the brain and spinal cord. The most commonly known prion diseases in human are Fatal Familial Insomnia, Creutzfeldt - Jakob disease (CJD), Gerstmann-Straussler-Scheinker Syndrome, and Kuru, and most commonly identified animal prion diseases are Transmissible mink encephalopathy, Bovine Spongiform Encephalopathy (BSE), Scrapie, and others.
BSE (bovine spongiform encephalopathy) is one of the most common neurological disorder found in cattle that results from a transmissible agent called a prion. According to the Centers for Disease Control and Prevention, five cases of BSE are found in the U.S. and 20 in Canada in 2017.
A number of factors such as rising facilities for patients affected by encephalopathy, increasing awareness among people, increasing government assistance, and improvement in regulatory framework are propelling the growth of the global spongiform encephalopathy market.
Despite these drivers, challenges in research and development, and poor healthcare system in low and middle-income countries may hamper the growth of the market.
It is estimated that spongiform encephalopathy market size expected to grow at a healthy CAGR of 6.1% during the forecast period 2017-2023.
Key Players
Teva Pharmaceuticals, Abbvie, Adamas Pharmaceuticals, Inc., Newron Pharmaceuticals SPA, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Lonza, Merck KGaA, Thermo Fisher Scientific Inc., and others.
Regional Analysis
The Asia Pacific is the fastest growing spongiform encephalopathy market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the year 2014-15.
Europe dominates the spongiform encephalopathy market owing to the high prevalence of bovine spongiform encephalopathy in European region, support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region
The Americas hold the second position in the spongiform encephalopathy market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the U.S. was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
The Middle East & Africa owns the least share of the global spongiform encephalopathy market due to lack of technical knowledge and poor medical facilities.
Segmentation
The spongiform encephalopathy market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into in humans, in animals. The human's segment is classified into Creutzfeldt-Jakob disease, Variant Creutzfeldt-Jakob disease (vCJD), others. The others segment includes Gerstmann-Sträussler-Scheinker disease, fatal familial insomnia, and kuru (Papua New Guinea). The animals segment is classified into bovine spongiform encephalopathy (BSE), Scrapie in sheep and goats, Chronic Wasting Disease (CWD), Feline spongiform encephalopathy, others. BSE is further classified into classical BSE and atypical BSE.
On the basis of the diagnosis, the market is classified into histopathology and immunohistochemistry, immunochemical detection methods, animal bioassays, cell culture assay systems, protein misfolding cyclic amplification, conformation-dependent immunoassay, capillary electrophoresis, fluorescent correlation spectroscopy, multispectral ultraviolet fluorescence spectroscopy, and Fourier transform infrared spectroscopy. Histopathology and Immunohistochemistry are further segmented into immunohistochemical staining and electron microscopy. Immunochemical Detection Methods is further segmented into Western Blotting Test, and Enzyme-Linked Immunosorbent Assay (ELISA).
On the basis of the treatment, the market is classified into small molecules, and immunotherapies. The small molecules are further classified into pentosan polysulfate, quinacrine, amphotericin B, and others. Immunotherapies are further classified into Antibody-based immunotherapies and Cell-Based Immunotherapies. Antibody-based immunotherapies include passive immunization, active immunization, and targeting disease-specific epitopes. Cell-based immunotherapies include DC vaccines and adoptive transfer of CD4+ T-cells.
On the basis of the end-users, the market is segmented into hospital & clinics, diagnostic centers veterinary hospitals, research & academic laboratories, and others.
Posted by at No comments:

Bone Scan Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020 - 2023

Market Synopsis of the Global Bone Scan Market
According to the WHO, about 59% of the mortality is due to chronic diseases and almost 35 million people die of chronic diseases across the globe.
The global bone scan market is expected to grow at a CAGR of 5.7% during the forecast period.
A bone scan is a test of nuclear medicine and is mostly used to diagnose various bone diseases such as arthritis and bone cancer. It includes an injection of radioactive material and then the bone scan. Radioactive material also known as the tracer is injected into a vein. After injecting this material, the radiologist performs a bone scan. The radiologist may perform the bone scan in phases depending upon the condition to be diagnosed such as the presence of bone disease or cancer.
Rising prevalence of bone disease, increasing demand for imaging devices such as MRI, CT scan, SPECT scan, and increasing health care services are accelerating the growth of the market. Furthermore, the increasing expenditure on medical devices influences the market growth. Technological advancements in radiology devices affecting the market growth. However, the efficiency of bone scan may hinder the market growth over the forecast period. Additionally, the bone scan may determine the inaccurate cause of the abnormality.
Key Players in the Global Bone Scan Market   
  • Siemens (U.S.)
  • Hitachi, Ltd. (Japan)
  • Carestream Health, Inc. (U.S.)
  • Samsung Electronics Co., Ltd. (South Korea)
  • Toshiba Corporation. (Japan)
  • Koninklijke Philips N.V. (Netherlands)
  • General Electric Company (U.S.)
Segments of the Global Bone Scan Market
The global bone scan market is segmented on the basis of product, indication, device, and end user.
On the basis of the product, the market is segmented into radiopharmaceuticals and imaging devices. The imaging devices are further segmented into Magnetic Resonance Imaging (MRI), X-ray, Computed Tomography (CT), Single-Photon Emission Computerized Tomography (SPECT), and others.
On the basis of the application, the market is segmented into fractures, arthritis, Paget's disease of bone, cancer originating in bone, and others.
On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Regional Analysis
The Americas lead the global bone scan market size owing to the rising prevalence of bone disorders in the U.S. Furthermore, increasing demand for diagnostic services in various also influences the market growth. In North America, the U.S. is the largest market followed by Canada. Increasing penetration of orthopedic specialty hospitals and healthcare insurance is adding fuel to the market growth. Furthermore, the concentration of key players in the market along with the availability of various technologically advanced devices is boosting the market growth in the U.S.
Europe is the second largest bone scan market across the globe. The market is accelerated by the extensive use of diagnostic devices for diagnosis of various chronic diseases such as arthritis, diabetes, obesity and others. Furthermore, extensive research and development (R&D) activities carried out by clinical research and academic institutes stimulate the growth of the market. Germany and France contribute to the growth of the market owing to increasing expenditure on R&D and extensive demand for diagnostic devcies.
The Asia Pacific market is expected to grow at the fastest pace due to the high prevalence of chronic disease such as rheumatoid arthritis, osteoarthritis, obesity, diabetes, and other. Additionally, increasing number of bone injuries such as bone fractures boost the growth of the market.  To add further, increasing number of skilled professionals along with increasing awareness about the bone diseases and importance of imaging tests in the diagnosis of bone diseases, and injuries. In Asia Pacific, India and China are holding the largest market share followed by Japan. Increasing expenditure on healthcare and improving healthcare infrastructure in various developing regions of Asia Pacific region are affecting the market growth, positively.
Posted by at No comments:
Subscribe to: Posts (Atom)